Monogram Technologies Inc. has announced that it will be acquired by Zimmer Biomet. According to the announcement, each common share of Monogram will be cancelled and automatically converted into the right to receive cash and a Contingent Value Right $(CVR)$. The merger is expected to close in the second half of 2025, contingent upon necessary approvals. Monogram shares will continue to be traded on Nasdaq until the merger's completion, after which the company will be delisted and become a wholly-owned subsidiary of Zimmer Biomet.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.